home / stock / xfor / xfor news

XFOR News and Press, X4 Pharmaceuticals Inc.

Stock Information
Company Name: X4 Pharmaceuticals Inc.
Stock Symbol: XFOR
Market: NYSE
Website: x4pharma.com
Menu
XFOR XFOR Quote XFOR Short XFOR News XFOR Articles XFOR Message Board
Get XFOR Alerts

News, Short Squeeze, Breakout and More Instantly...
XFOR - US Companies Moving the Markets, Evening edition
Thu, Jun 27, 2024 as of 4:00 pm ET

A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 30.9% to $0.6 on volume of 558,931,853 shares NVIDIA Corporation (NVDA) fell 1.9% to $123.99 on volume of 249,243,816 shares Assure Holdings Corp. (IONM) rose 82.8% to $0.424 on vol...
XFOR - X4 slips after mid-stage data for lead drug in neutropenia

2024-06-27 13:40:16 ET More on X4 Pharmaceuticals X4 Pharmaceuticals Inc (XFOR) Q1 2024 Earnings Call Transcript X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside X4 Pharmaceuticals: PDUFA Excitement Ahead X4 Pharma gains on new $125 financing...

XFOR - X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increase with once-daily, oral mavorixafor +/- stable-dose G-CSF as of the interim analysis data cut-off date Durable mean ANC levels above the lower limit of normal for CN were achieved for partic...

XFOR - X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will host a virtual investor event on Thursday, June 27, 2024 at 8:00 am ET. To register for the eve...
XFOR - X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in the upcoming H.C. Wainwright 2 nd Annual BioConnect Investor Co...

XFOR - X4 Pharma gains on new $125 financing

2024-05-09 07:30:10 ET More on X4 Pharmaceuticals X4 Pharmaceuticals Inc (XFOR) Q1 2024 Earnings Call Transcript X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside X4 Pharmaceuticals: PDUFA Excitement Ahead X4 Pharmaceuticals GAAP EPS of -$0.26...

XFOR - X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

$125 million of non-dilutive capital extends projected cash runway into late 2025, excluding expected commercial sales from XOLREMDI™ (mavorixafor) XOLREMDI, the first drug indicated in patients with WHIM syndrome, received U.S. FDA approval in April 2024 BOSTON, May 09, 2024...
XFOR - X4 Pharmaceuticals Inc (XFOR) Q1 2024 Earnings Call Transcript

2024-05-07 13:33:09 ET X4 Pharmaceuticals Inc (XFOR) Q1 2024 Results Conference Call May 07, 2024 8:30 AM ET Company Participants Dan Ferry - IR Paula Ragan - CEO Adam Mostafa - CFO Christophe Arbet-Engels - COO Mark Baldry - CMO Conference Call Par...

XFOR - X4 Pharmaceuticals GAAP EPS of -$0.26

2024-05-07 06:05:57 ET More on X4 Pharmaceuticals X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside X4 Pharmaceuticals: PDUFA Excitement Ahead X4 gets FDA approval for Xolremdi for WHIM syndrome X4 Pharmaceuticals GAAP EPS of -$0.10 beats by $...

XFOR - X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

U.S. launch underway for XOLREMDI™ (mavorixafor) in WHIM syndrome XOLREMDI Phase 3 4WHIM clinical trial data published online in Blood , the journal of the American Society of Hematology Presentation of interim clinical data from the ongoing mavorixafor Phase 2 ...
Next 10